Effect of valproic acid on the outcome of glioblastoma multiforme

British Journal of Neurosurgery

Volumn 26, Issue 3, 2012, Pages 347-354

  Tsai, Hong Chieh ^a,b   Wei, Kuo Chen ^a   Tsai, Chi Neu ^b   Huang, Ying Cheng ^a   Chen, Pin Yuan ^a   Chen, Shu Mei ^a   Lu, Yu Jen ^a   Lee, Shih Tseng ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Glioblastoma multiforme; Histone deacetylase inhibitor; Valproic acid

Indexed keywords

CISPLATIN; ETOPOSIDE; HISTONE DEACETYLASE; TEMOZOLOMIDE; THALIDOMIDE; VALPROIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHILD; DISEASE CONTROL; DIZZINESS; DRUG EFFECT; ENZYME INHIBITION; EPIGENETICS; FEBRILE NEUTROPENIA; FEMALE; GENE CONTROL; GENE FUNCTION; GLIOBLASTOMA; HISTONE ACETYLATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SEIZURE; THROMBOCYTOPENIA; THROMBOEMBOLISM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CHILD; ENZYME INHIBITORS; FEMALE; GLIOBLASTOMA; HISTONE ACETYLTRANSFERASES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VALPROIC ACID; YOUNG ADULT;

EID: 84861620928     PISSN: 02688697     EISSN: 1360046X     Source Type: Journal    
DOI: 10.3109/02688697.2011.638996     Document Type: Article

References (44)

1. Hess KR, Broglio KR, Bondy ML. Adult glioma incidence trends in the United States, 1977-2000. Cancer 2004;101:2293-9.
2. A lbert FK, Forsting M, Sartor K, Adams HP, Kunze S. Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its infl uence on regrowth and prognosis. Neurosurgery 1994;34: 45-60; discussion 60-41.
3. L acroix M, Abi-Said D, Fourney DR, et al.. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001;95:190-8.
4. D e Sanctis V, Mazzarella G, Osti MF, et al.. Radiotherapy and sequential temozolomide compared with radiotherapy with concomitant and sequential temozolomide in the treatment of newly diagnosed glioblastoma multiforme. Anticancer Drugs 2006;17:969-75.
5. S tupp R, Hegi ME, Mason WP, et al.. Eff ects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66.
6. S tupp R, Mason WP, van den Bent MJ, et al.. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
7. E rpolat OP, Akmansu M, Goksel F, Bora H, Yaman E, Buyukberber S. Outcome of newly diagnosed glioblastoma patients treated by radiotherapy plus concomitant and adjuvant temozolomide: a long-term analysis. Tumori 2009;95:191-7.
8. A shby LS, Ryken TC. Management of malignant glioma: steady progress with multimodal approaches. Neurosurg Focus 2006;20:E3.
9. Tran B, Rosenthal MA. Survival comparison between glioblastoma multiforme and other incurable cancers. J Clin Neurosci 2010; 17:417-21.
10. Marks PA, Richon VM, Breslow R, Rifkind RA. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 2001;13: 477-83.
11. M arks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of diff erentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000;92:1210-16.
12. C hen X, Wong P, Radany E, Wong JY. HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells. Cancer Biother Radiopharm 2009;24:689-99.
13. Sarkar D. HDAC inhibitors and ionizing radiation: combinatorial strategy to combat lung cancer. Cancer Biol Ther 2009;8:832-4.
14. Beumer JH, Tawbi H. Role of histone deacetylases and their inhibitors in cancer biology and treatment. Curr Clin Pharmacol 2010;5:196-208.
15. N oro R, Miyanaga A, Minegishi Y, et al.. Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21 expression. Cancer Sci 2010;101:1424-30.
16. Duvic M, Talpur R, Ni X, et al.. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007;109:31-9.
17. Kavanaugh SA, White LA, Kolesar JM. Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma. Am J Health Syst Pharm 2010;67:793-7.
18. G alanis E, Jaeckle KA, Maurer MJ, et al.. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 2009;27:2052-8.
19. P hiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001;276:36734-41.
20. B laheta RA, Michaelis M, Driever PH, Cinatl J, Jr. Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med Res Rev 2005;25:383-97.
21. Candelaria M, Gallardo-Rincon D, Arce C, et al.. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol 2007;18:1529-38.
22. N oguchi H, Yamashita H, Murakami T, Hirai K, Noguchi Y, Maruta J, et al.. Successful treatment of anaplastic thyroid carcinoma with a combination of oral valproic acid, chemotherapy, radiation and surgery. Endocr J 2009;56:245-9.
23. R occa A, Minucci S, Tosti G, et al.. A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. Br J Cancer 2009;100:28-36.
24. R yningen A, Stapnes C, Lassalle P, Corbascio M, Gjertsen BT, Bruserud O. A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid. Leuk Res 2009;33:779-87.
25. Sharma S, Symanowski J, Wong B, Dino P, Manno P, Vogelzang N. A Phase II Clinical Trial of Oral Valproic Acid in Patients with Castration-Resistant Prostate Cancers Using an Intensive Biomarker Sampling Strategy. Transl Oncol 2008;1:141-7.
26. Tan J, Cang S, Ma Y, Petrillo RL, Liu D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 2010;3:5.
27. Driever PH, Knupfer MM, Cinatl J, Wolff JE. Valproic acid for the treatment of pediatric malignant glioma. Klin Padiatr 1999;211:323-8.
28. D riever PH, Wagner S, Hofstadter F, Wolff JE. Valproic acid induces diff erentiation of a supratentorial primitive neuroectodermal tumor. Pediatr Hematol Oncol 2004;21:743-51.
29. Oberndorfer S, Piribauer M, Marosi C, Lahrmann H, Hitzenberger P, Grisold W. P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neurooncol 2005;72:255-60.
30. Witt O, Schweigerer L, Driever PH, Wolff J, Pekrun A. Valproic acid treatment of glioblastoma multiforme in a child. Pediatr Blood Cancer 2004;43:181.
31. Gaspar L, Scott C, Rotman M, et al.. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997;37:745-51.
32. Miller P J, Hassanein RS, Giri PG, Kimler BF, O 'Boynick P, Evans RG. Univariate and multivariate statistical analysis of high-grade gliomas: the relationship of radiation dose and other prognostic factors. Int J Radiat Oncol Biol Phys 1990;19:275-80.
33. O zbek N, Cakir S, Gursel B, Meydan D. Prognostic signifi cance of seizure in patients with glioblastoma multiforme. Neurol India 2004;52:76-8.
34. W inger MJ, Macdonald DR, Cairncross JG. Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma. Journal of Neurosurgery 1989;71:487-93.
35. J aeckle KA, Ballman K, Furth A, Buckner JC. Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma. Neurology 2009;73:1207-13.
36. F rediani F. Anticonvulsant drugs in primary headaches prophylaxis. Neurol Sci 2004;25:S161-6.
37. L imdi NA, Knowlton RK, Cofield SS, et al.. Safety of rapid intravenous loading of valproate. Epilepsia 2007;48:478-83.
38. Wolff JE, Kramm C, Kortmann RD, et al.. Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma. J Neurooncol 2008;90:309-314.
39. M asoudi A, Elopre M, Amini E, et al.. Infl uence of valproic acid on outcome of high-grade gliomas in children. Anticancer Res 2008;28:2437-42.
40. Benitez JA, Arregui L, Cabrera G, Segovia J. Valproic acid induces polarization, neuronal-like diff erentiation of a subpopulation of C6 glioma cells and selectively regulates transgene expression. Neuroscience 2008;156:911-20.
41. Das CM, Aguilera D, Vasquez H, et al.. Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines. J Neurooncol 2007;85:159-70.
42. Knupfer MM, Hernaiz-Driever P, Poppenborg H, Wolff JE, Cinatl J. Valproic acid inhibits proliferation and changes expression of CD44 and CD56 of malignant glioma cells in vitro. Anticancer Res 1998;18:3585-9.
43. Camphausen K, Cerna D, Scott T, et al.. Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int J Cancer 2005;114:380-6.
44. C iusani E, Balzarotti M, Calatozzolo C, et al.. Valproic acid increases the in vitro eff ects of nitrosureas on human glioma cell lines. Oncol Res 2007;16:453-63.